TSX closed
Loading markets…

Advertisement

Stocks

Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:CRDL.TO

Follow CRDL

Photos provided by Pexels

With a history of exceeding expectations, Cardiol Therapeutics Inc Class A is about to report its earnings soon. Investors are closely watching to see if it can keep this trend going.

Cardiol Therapeutics Inc Class A (CRDL.TO) will release its next earnings report on August 13, 2026, after the market closes. The pharmaceutical company is in the spotlight as it prepares to share its financial results for the fiscal period ending June 30, 2026. With a consensus EPS estimate of -$0.10, market participants are eager to find out if Cardiol can maintain its recent track record of beating earnings expectations.

Recent earnings trend

Advertisement

Cardiol Therapeutics Inc Class A

CRDL.TO

Full stock page →

CRDL.TO

Cardiol Therapeutics Inc Class A

Source:WealthAwesomeWealthAwesome
↑ $0.34 (17.99%)
120 day period
$1.44$2.30$3.16Apr 13Jul 8Oct 1

Market cap

$270.97M

52W high

$3.23

52W low

$1.23

1W change

-8.23%

Beta

0.61

Analyst Price Targets

Based on analyst covering CRDL · as of Sep 17, 2026

📈

Wall Street analysts forecast CRDL stock price to rise 284.6% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$6.00

+284.6% Upside

Current Price

C$1.56

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on CRDL's historical volatility

HistoricalForecast68%95%
C$1.10C$2.17C$3.25C$4.33C$5.40C$6.48TodayMay 26Jul 29Oct 1Nov 13Dec 27Feb 8

30-Day Vol

71.8%

Annualized

90-Day Vol

63.7%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$2.67

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$2.37C$1.85 – C$3.03
60 trading daysC$2.51C$1.77 – C$3.57
90 trading daysC$2.67C$1.74 – C$4.09

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Analyst coverage: 3 analyst(s) cover this name; upcoming EPS consensus is available.

Beat estimates in 3 of the last 4 comparable quarter(s).

Fiscal periodReport dateActual EPSEstimateSurprise
2026-06-302026-08-13—-0.1000—
2026-03-312026-05-12-0.0719-0.0900+20.1%
2025-12-312026-03-31-0.0700-0.1100+36.4%
2025-09-302025-11-13-0.1200-0.1000-20.0%
2025-06-302025-08-14-0.1000-0.1200+16.7%
2025-03-312025-05-14-0.1000-0.1300+23.1%
-0.1800-0.09000.0000 24-0624-0924-1225-0325-0625-0925-1226-03 Estimate Actual (≥0) Actual (<0) Wealth Awesome

Advertisement

Investor takeaway: Keep an eye on the company’s recent performance history. Cardiol has surpassed earnings estimates in three out of its last four quarters. The upcoming report will be crucial in determining whether this trend continues, especially given the current EPS estimate and the company’s recent advancements in clinical trials.

EPS Estimate: -$0.10, Historical Beat Rate: 75%

Cardiol has beaten earnings estimates in three of the last four quarters, showing a strong ability to exceed expectations despite a generally negative EPS outlook.

Bull case

The bull case for Cardiol is based on its solid history of earnings surprises and recent positive developments in clinical research. Notably, the results from its Phase II study were published in a reputable journal. This could boost investor confidence and potentially lead to higher stock prices.

Bear case

On the other hand, the company still faces challenges with a negative EPS and no revenue expected for the upcoming quarter. If the earnings report falls short of even the lowered expectations, it could lead to a sharp decline in investor sentiment.

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 12, 2026
Last Updated: August 12, 2026

Core portfolio

Awesome Portfolio™

15.1% a year since 2017, against 9.9% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+15.1%

Awesome Portfolio™

+9.9%

S&P/TSX

+5.2 pp better a year

Total return

+260%

Awesome Portfolio™

+137%

S&P/TSX

+123 pp better than the TSX

2017-07-31 to 2026-09-17, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-17
-11.7%42.8%97.2%151.6%206.0%260.4%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement